Evidence map›Paper›PMID 34811492›Full record

ArticleCommunications biology2021

Transcript-targeted analysis reveals isoform alterations and double-hop fusions in breast cancer.

Shinichi Namba, Toshihide Ueno, Shinya Kojima, Kenya Kobayashi, Katsushige Kawase, Yosuke Tanaka, Satoshi Inoue, Fumishi Kishigami, Shusuke Kawashima, Noriko Maeda and 7 more

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. CirculatingCancers · 2026
    Article
  3. Article
  4. Long-read RNA sequencing: A transformative technology for exploring transcriptome complexity in human diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Shinichi NambaDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Toshihide UenoDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.ORCID http://orcid.org/0000-0002-7408-7298
Shinya KojimaDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Kenya KobayashiDepartment of Head and Neck Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Katsushige KawaseDivision of Cell Therapy, Chiba Cancer Center, Research Institute, Chiba, 260-8717, Japan.ORCID http://orcid.org/0000-0001-6998-8481
Yosuke TanakaDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.ORCID http://orcid.org/0000-0002-3764-0517
Satoshi InoueDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Fumishi KishigamiDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.ORCID http://orcid.org/0000-0003-4052-2842
Shusuke KawashimaDivision of Cell Therapy, Chiba Cancer Center, Research Institute, Chiba, 260-8717, Japan.
Noriko MaedaDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Yamaguchi, 755-8505, Japan.
Tomoko OgawaDepartment of Breast Surgery, Mie University Hospital, Mie, 514-8507, Japan.ORCID http://orcid.org/0000-0002-1769-8260
Shoichi HazamaDepartment of Translational Research and Developmental Therapeutics against Cancer, Yamaguchi University Graduate School of Medicine, Yamaguchi, 755-8505, Japan.
Yosuke TogashiDivision of Cell Therapy, Chiba Cancer Center, Research Institute, Chiba, 260-8717, Japan.
Mizuo AndoDepartment of Otolaryngology, Head and Neck Surgery, The University of Tokyo Hospital, Tokyo, 113-8654, Japan.ORCID http://orcid.org/0000-0002-0754-2545
Yuichi ShiraishiDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Hiroyuki ManoDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.ORCID http://orcid.org/0000-0003-4645-0181
Masahito KawazuDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, 104-0045, Japan. mkawz-tky@umin.ac.jp.ORCID http://orcid.org/0000-0003-4146-3629
Chiba Cancer Center · JPYamaguchi University · JPMie University Hospital · JPThe University of Osaka · JPUniversity of Tokyo Hospital · JP

Funding

MEXT | Japan Society for the Promotion of Science (JSPS) 16K07143MEXT | Japan Society for the Promotion of Science (JSPS) 21H02772
6 · The paper itself

Abstract

Although transcriptome alteration is an essential driver of carcinogenesis, the effects of chromosomal structural alterations on the cancer transcriptome are not yet fully understood. Short-read transcript sequencing has prevented researchers from directly exploring full-length transcripts, forcing them to focus on individual splice sites. Here, we develop a pipeline for Multi-Sample long-read Transcriptome Assembly (MuSTA), which enables construction of a transcriptome from long-read sequence data. Using the constructed transcriptome as a reference, we analyze RNA extracted from 22 clinical breast cancer specimens. We identify a comprehensive set of subtype-specific and differentially used isoforms, which extended our knowledge of isoform regulation to unannotated isoforms including a short form TNS3. We also find that the exon-intron structure of fusion transcripts depends on their genomic context, and we identify double-hop fusion transcripts that are transcribed from complex structural rearrangements. For example, a double-hop fusion results in aberrant expression of an endogenous retroviral gene, ERVFRD-1, which is normally expressed exclusively in placenta and is thought to protect fetus from maternal rejection; expression is elevated in several TCGA samples with ERVFRD-1 fusions. Our analyses provide direct evidence that full-length transcript sequencing of clinical samples can add to our understanding of cancer biology and genomics in general.

Indexed as

Gene FusionTranscriptomeBreast NeoplasmsHumansProtein IsoformsRNATensinsProtein IsoformsRNATensinsTNS3 protein, human

Identifiers

PMID34811492
PMCPMC8608905
OpenAlexW3215217658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.